Abstract Light chain amyloidosis (AL) involves multiorgan failure induced by amyloidogenic light chain proteins, and is associated with high mortality. We aimed to identify clinical, laboratory, and imaging parameters that would predict 1-year and long-term AL mortality. Fortyfour biopsy-proven AL patients (61.5 ± 12 years, 20 females) underwent clinical evaluation including laboratory assays, echocardiography, and contrast cardiac magnetic resonance imaging (CMR, n = 31) prior to chemotherapy. Patients were prospectively followed for median duration of 62.7 months (interquartile range 35.5 months). Clinical and laboratory parameters were compared between 1-year survivors and nonsurvivors. Univariate Kaplan-Meier survival plots were calculated followed by stepwise logistic regression analysis to assess independent predictors of long-term survival. Eighteen (40.9 %) patients died within 1 year and an additional 10 subjects died during long-term follow-up. Patients who expired within 1 year presented with more advanced class of heart failure, higher alkaline phosphatase and uric acid, lower limb lead voltage on electrocardiography, shorter left ventricular ejection time (ET) on echocardiography, and a higher proportion of late gadolinium enhancement on CMR. On multivariable analysis, only ET B240 ms on echocardiography (hazard ratio (HR) 5.07, 95 % confidence interval (CI) 1.83-14.1, P = 0.002) and New York Heart Association functional class II-IV presentation (HR 1.0058, 95 % CI 1.0014-1.0103, P = 0.01) were independent predictors of AL mortality. In conclusion, AL amyloidosis is associated with high 1-year and long-term mortality. Among clinical, laboratory, and imaging parameters tested, an echocardiographic finding of ET B240 ms has independent and additive prognostic value to clinical heart failure evaluation in determining long-term survival of AL patients. This result may be important in the early identification of patients at risk.
Introduction
Light chain amyloidosis (AL) involves cardiac and multiorgan dysfunction induced by circulating and deposited amyloidogenic immunoglobulin light chain proteins produced by a clonal population of plasma cells [1, 2] . It is associated with increased morbidity and mortality, with cardiac involvement leading to cardiac decompensation being the most important cause of death. Identifying clinical, laboratory, and imaging parameters associated with early and long-term mortality may be important in risk stratification. Prior reports by our group and others showed the prognostic utility of echocardiography, specifically left ventricular ejection time (ET) [3, 4] , in predicting AL mortality, whereas evidence of the independent prognostic value of late gadolinium enhancement (LGE) from cardiac magnetic resonance imaging (CMR) on AL mortality has been variable [5] [6] [7] [8] . Despite publication of these earlier reports, the comparative roles of ET and LGE versus each other as well as other clinical, laboratory, and electrocardiographic parameters as predictors of long-term (5-year) AL mortality have not been studied. We are testing the hypothesis that ET and LGE are independent predictors of long-term AL mortality, and that they have additive prognostic value to clinically determined heart failure (HF) presentation.
Patients and methods

Patient population
Between May 2005 and October 2009 , 44 consecutive patients with biopsy-proven diagnosis of AL amyloidosis and elevated j or k immunoglobulin light chains on urine or serum seen at the Medical College of Wisconsin were prospectively included in the study. The study was approved by the local institutional review board. Thirtynine subjects provided informed consent to be part of the longitudinal study of AL. Five subjects with suspected AL awaiting tissue confirmation of diagnosis to qualify for study enrollment died before recruitment to the study, and waiver of consent authorization was obtained from the institutional review board for data collection. All five subjects were subsequently found to have biopsy evidence of amyloidosis and elevated light chains on serum or urine. They were included in the analysis to fully capture all consecutive patients with AL amyloidosis seen at the institution. The survival status was verified from hospital or outpatient records; Social Security Death Index was also used for verification until September 2009.
Clinical and laboratory evaluation
Presenting New York Heart Association (NYHA) HF functional class (I-IV) was assessed after enrollment and was adjudicated by a cardiologist on the basis of presenting symptoms and signs according to well-established clinical standards [9] . Data on age, gender, systolic blood pressure, heart rate, and laboratory values of creatinine, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, troponin, uric acid, and brain natriuretic peptide (BNP) were obtained. Standard 12-lead electrocardiography (ECG) was performed. Low-voltage ECG was defined as voltage of B5 mV in all limb leads [10] .
Echocardiography and CMR
The details of the methods have been previously published for echocardiography [4] and CMR [7] . In brief, routine clinical echocardiography was performed using the General Electric Vivid 7 (GE, Waukesha, WI, USA) or Philips IE 33, 7500, or 5500 (Philips Medical, Bothell, WA, USA). Our previous publication [4] showed the prognostic significance of left ventricular ET, and we again included this measurement in our multivariable modeling. ET was measured as the duration of flow using standard pulsed-wave Doppler with sample volume located in the left ventricular outflow tract just below the aortic valve leaflets. Left ventricular ejection fraction was obtained using the area length method from the four-chamber view [11] . Of the 44 AL subjects, 31 underwent CMR studies. Standard CMR methods were performed for LGE imaging. A General Electric 1.5-T CV scanner with 8-channel cardiac coil was used. Gadolinium, 0.1 mmol/kg (gadodiamide, GE Healthcare, Little Chalfont, UK or gadobenate dimeglumine, Bracco Diagnostics, Monroe, NJ, USA) was injected followed by imaging after an approximately 5-min delay in short-axis and multiple long-axis views. Gated segmented inversion-recovery prepared gradient-echo pulse sequence was done with a field of view of 38-42 cm, matrix of 256 9 192-256, slice thickness of 7-8 mm, and interslice gap of 2-3 mm, inversion time adjusted to null normal myocardium (*175-300 ms), 1-2 excitations, and 2 R-R intervals. The details of the determination of the optimal inversion time have been reported previously [7] . Two expert CMR readers (R.Q.M. and R.C.) independently adjudicated the presence or absence of LGE, with agreement of the findings in all cases.
Data and statistical analyses
Data are expressed as mean ± standard deviation (SD). Continuous variables were compared between groups using Student's t test or Mann-Whitney rank sum test for normal or non-normal distribution data, respectively. Categorical variables were compared using the Chi-square test or Fisher's exact test (in cases where a category bin n B 5). Significant P value was set at P\0.05. Stratified estimates of survival probabilities were computed using KaplanMeier estimators [12] and a log-rank test was used to test for group differences in survival curves from all-cause mortality (MedCalc 9.6.4.0, Mariakerke, Belgium). The cutoff values for ET and alkaline phosphatase used for dichotomy were derived from receiver-operating characteristic (ROC) curve analysis to determine the sensitivity and specificity in predicting 1-year mortality among patients who were censored or alive after 1 year of followup. Variables associated with 1-year mortality were entered into a Cox stepwise multivariable analysis (variable removed if P [ 0.1 and entered if P \ 0.05) to derive the final model for prediction of all-cause mortality (MedCalc 9.6.4.0). No data imputation was performed.
Results
Within 1 year of study inclusion, 18 of 44 patients died (40.9 %) and during long-term follow-up, an additional 10 patients expired. The most common cause of mortality involved multiorgan failure (Table 1) . Direct cardiac contribution to the cause of death was found in 14 of 25 (56 %) deaths with known causes.
Patients who expired within 1 year of study inclusion had significantly more advanced class of HF, higher alkaline phosphatase levels, lower limb lead voltages on ECG, had a higher proportion of presence of LGE on CMR, and had shorter left ventricular ET on echocardiography ( Table  2 ). The proportion receiving autologous stem cell transplantation is also less in nonsurvivors in comparison with survivors (Table 2) . Thirty-eight patients (86 %) received chemotherapy, and melphalan was the most commonly used chemotherapeutic agent (Table 3) .
ROC curve analyses showed that alkaline phosphatase level of 85 IU/l (area under the curve (AUC) 0.73, P = 0.004) and ET of 240 ms (AUC 0.68, P \ 0.04) had the best ability to discriminate between 1-year survivors and nonsurvivors.
On univariate analysis, HF class II-IV, LVET B240 ms, alkaline phosphatase C85 IU/l, nonutilization of autologous stem cell transplantation, presence of low voltage on ECG, and LGE on CMR, but not serum uric acid, were associated with poor long-term survival (Fig. 1) . Following logistic regression analysis wherein each of these variables were put in the model using a stepwise analysis, only LVET B240 ms (hazard ratio (HR) 5.07, 95 % confidence interval (CI) 1.83-14.1, P = 0.002) and HF class II-IV (HR 1.0058, 95 % CI 1.0014-1.0103, P = 0.01) were found to be independent predictors of long-term AL mortality (overall model fit v 2 15.7, P = 0.0004). Kaplan-Meier analysis was performed to assess survival of subjects stratified as to whether they have HF (class II-IV), LVET B240 ms, both, or neither (Fig. 2) . Subjects who had both had the worst prognosis while subjects with neither had the best survival.
Discussion
We report the novel observation that on long-term (median [5 years) follow-up, left ventricular ET using echocardiography is an important independent predictor of long-term AL mortality and has additive prognostic value to HF class presentation. Our results show that in addition to ET and HF classification, presence of LGE, low voltage on ECG, increased uric acid, and increased alkaline phosphatase are associated with increased 1-year mortality, while eligibility for and treatment with autologous stem cell transplant with chemotherapy is associated with reduced 1-year mortality. These findings may be important in early risk stratification of AL subjects. Of further importance, despite use of chemotherapy in 88.6 % of patients, 1-year mortality was 40.9 %, and 63.6 % of AL patients expired during the study follow-up. Although amyloidogenic light chain proteins are deposited in multiple organs such as the liver, gastrointestinal tract, kidneys, and peripheral nerves, the major causes of morbidity and mortality in AL involve cardiac complications, notably HF and arrhythmias/sudden cardiac death [1, 2] . There is increasing clinical [13] [14] [15] [16] and preclinical evidence [17] [18] [19] that the major toxic species in AL is the soluble prefibrillar species. This is supported by disease stabilization following eradication of clonal plasma cells producing light chain proteins through chemotherapy ± autologous stem cell transplantation, currently the only treatment available for the disease, despite persistence of amyloid deposits [13, 15] . Toxicity to the cardiovascular system involves amyloid deposition in the cardiac interstitium, leading to cardiomyocyte toxicity [17] [18] [19] , as well as oxidative stress and apoptotic injury to the microvessels and endothelial cells [20] [21] [22] . Because of the critical role of cardiac involvement in the disease course, clinical, laboratory, and imaging studies that define the presence and extent of cardiac involvement are important in disease management. Evidence of cardiac involvement includes diffuse low voltage on ECG, elevation of cardiac biomarkers such as troponins, BNP and N-terminal proBNP, and thickening of the left ventricle on echocardiography or CMR despite absence of hypertrophy on ECG. The presence of LGE on CMR with distinct subendocardial or diffuse myocardial distribution, as well as unusual gadolinium kinetics that reflect myocardial levels close to blood pool levels, has recently been available as a clinical tool to noninvasively establish cardiac involvement, reducing the need for invasive endomyocardial biopsy [1, 2, [5] [6] [7] [8] 23] .
The medium-term prognostic value of CMR or echocardiography for predicting AL mortality have separately been reported by our group and others. LGE on CMR was found to be associated with poor survival even after adjustment for HF class (median follow-up 29 months) in the same cohort of patients [7] , but other investigators found that LGE presence did not add prognostic value to HF class in predicting AL mortality at median follow-up durations of 29 months [8] , 21 months [5] , and[32 months [6] . Maceira et al. [5] , however, reported that the difference in gadolinium distribution between subepicardial and subendocardial myocardial regions assessed by T1 signal, and not the gross presence of LGE, is predictive of AL mortality. In separate reports not involving CMR imaging, we and others reported that left ventricular ET on echocardiography is a strong independent predictor of AL mortality at median follow-up durations of 29 months [4] and 18 months [3] . As far as we are aware, our findings are the first to compare the 5-year independent prognostic value of the two most commonly used imaging techniques to assess cardiac involvement in AL, CMR and echocardiography, with that of other clinical and laboratory parameters. The findings enhance the justification for the use of these diagnostic imaging modalities to assess 1-year and longterm risk of AL subjects.
The finding that LGE is not an independent predictor of long-term AL mortality is consistent with the observations of other investigators [5, 6, 8] , although 1-year mortality was higher in patients with LGE on CMR than in those without. This likely reflects the collinearity between LGE presence and extent of HF class presentation. The basis for the long-term prognostic value of ET remains undetermined. Left ventricular ET is an old, established measure of left ventricular performance that has been used to assess valvular, coronary artery, pericardial, hypertensive, and amyloid diseases [24] [25] [26] [27] [28] . In AL, short ET may reflect the inability of the infiltrated myocardium to increase enddiastolic volumes, prolongation of pre-ejection period due to myocardial dysfunction, and abnormal ventriculoatrial coupling [4, [27] [28] [29] . Further mechanistic studies need to be performed to establish the pathophysiologic basis of why short ET is strongly associated with AL mortality independent of HF class presentation. On the other hand, ET is easily measured from well-established routine echocardiography clinical protocols, and should be routinely measured and reported in AL patients to enhance patients' risk stratification. Clinically, autologous stem cell transplantation allows for utilization of more intensive chemotherapy regimens to eradicate clonal plasma cells producing amyloidogenic light chain proteins, but it is associated with increased mortality in patients with advanced HF [30] . Therefore, oncologists use a risk-adapted approach to determine eligibility for stem cell transplantation, which makes patients with advanced cardiac involvement ineligible for the procedure [30, 31] . It is therefore not surprising that when stem cell transplantation was put in the model with HF class, it fell off as an independent predictor because of the collinearity between HF class and eligibility for receiving stem cell transplantation. In light of the prognostic value of ET in AL, the addition of ET in the risk-adapted approach to determine eligibility for stem cell transplantation needs to be further studied. Furthermore, use of imaging and clinical parameters found to be useful in detecting cardiac involvement and predicting short-and long-term risk could enhance the current practice of comprehensive patient assessment that might have some impact on the overall adverse outcomes of these patients.
It is important to point out that the current study is an extension and expansion of our previously published work on the prognostic use of echocardiography [4] and CMR [7] . Although derived from the same cohort of subjects as the previous studies, the important novel observations of the current study are validating the independent prognostic value on 5-year follow-up and evaluating for the first time, using multivariable modeling, the prognostic value of relevant echocardiographic and CMR parameters in comparison with each other and with clinical parameters, which might be helpful to providers in making clinical decisions.
Study limitations
The study has several important limitations. The sample size involved in the study is small, although the number of mortality events during follow-up (28 of 44 patients) resulting from this often fatal disease somewhat mitigates this limitation as far as data analysis is concerned. The findings need to be validated by other long-term studies involving a larger population size. We did not have data on differential T1 signal on CMR LGE between epicardium and endocardium [5] , echocardiographic myocardial strain [3] , and N-terminal proBNP [32] , which have previously been reported to have independent prognostic value in AL, and therefore their relative value to ET and HF class remain unknown. In addition, we did not have imaging data on T2-weighted myocardial characteristics, which other investigators have shown to have potential prognostic value in cardiac amyloidosis [33] and other types of cardiomyopathy [34] .
Conclusions
AL remains a highly lethal disease despite utilization of chemotherapy with or without the use of autologous stem cell transplantation. Identification of clinical, laboratory, and imaging predictors of short-term and long-term survival is important in the risk stratification of patients. Short left ventricular ET on echocardiography (B240 ms) is an independent prognostic marker of short-term and long-term AL mortality in addition to HF class presentation.
